Download MendeleyNovel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.
Hurley, C.A., Blair, W.S., Bull, R.J., Chang, C., Crackett, P.H., Deshmukh, G., Dyke, H.J., Fong, R., Ghilardi, N., Gibbons, P., Hewitt, P.R., Johnson, A., Johnson, T., Kenny, J.R., Kohli, P.B., Kulagowski, J.J., Liimatta, M., Lupardus, P.J., Maxey, R.J., Mendonca, R., Narukulla, R., Pulk, R., Ubhayakar, S., van Abbema, A., Ward, S.I., Waszkowycz, B., Zak, M.(2013) Bioorg Med Chem Lett 23: 3592-3598
- PubMed: 23642482
- DOI: https://doi.org/10.1016/j.bmcl.2013.04.018
- Primary Citation of Related Structures:
4I5C - PubMed Abstract:
The identification of a novel fused triazolo-pyrrolopyridine scaffold, optimized derivatives of which display nanomolar inhibition of Janus kinase 1, is described. Prototypical example 3 demonstrated lower cell potency shift, better permeability in cells and higher oral exposure in rat than the corresponding, previously reported, imidazo-pyrrolopyridine analogue 2. Examples 6, 7 and 18 were subsequently identified from an optimization campaign and demonstrated modest selectivity over JAK2, moderate to good oral bioavailability in rat with overall pharmacokinetic profiles comparable to that reported for an approved pan-JAK inhibitor (tofacitinib).
Organizational Affiliation:
Department of Medicinal Chemistry, Argenta, 8/9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom. Chris.Hurley@glpg.com
